Biotech News
Related news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-06-13 11:30 EST
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CRSPCRISPR Therapeutics2026-09-08 12:30 EST
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPTSarepta Therapeutics2026-05-13 20:30 EST
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CRSPCRISPR Therapeutics2026-05-06 12:30 EST
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
KRYSKrystal Biotech2026-09-03 12:00 EST
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
SANASana Biotechnology2026-05-05 20:05 EST
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
CRBUCaribou2026-05-27 20:05 EST
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
SANASana Biotechnology2026-09-01 20:05 EST
Sana Biotechnology to Present at September 2026 Investor Conferences
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-09-04 20:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-09-04 12:50 EST
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
NTLAIntellia2026-09-04 12:00 EST
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
NTLAIntellia2026-08-07 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 12.26 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States